Free Trial
→ Before you buy SpaceX shares, consider this alternative approach (From Weiss Ratings) (Ad)tc pixel
NASDAQ:AIMD

Ainos Q4 2025 Earnings Report

Ainos logo
$1.74 +0.01 (+0.29%)
As of 02:24 PM Eastern
This is a fair market value price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Ainos EPS Results

Actual EPS
-$0.85
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Ainos Revenue Results

Actual Revenue
$0.01 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Ainos Announcement Details

Quarter
Q4 2025
Date
3/30/2026
Time
After Market Closes
Conference Call Date
Monday, March 30, 2026
Conference Call Time
7:00AM ET

Upcoming Earnings

Ainos' Q1 2026 earnings is estimated for Monday, May 11, 2026, based on past reporting schedules, with a conference call scheduled at 9:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Ainos' Q4 2025 Press ReleasePress Release
(8-K)
Ainos' Q4 2025 Annual reportAnnual report
(10-K)

Ainos Earnings Headlines

Ainos, Inc.: VASRO: Ainos Expands Smell AI from Industrials into Healthcare Infrastructure, Reinforcing AI Infrastructure Positioning and Multi-Vertical Scalability
April 17, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-04/68228895-ainos-inc-vasro-ainos-expands-smell-ai-from-industrials-into-healthcare-infrastructure-reinforcing-ai-infrastructure-positioning-and-multi-vertic-200.htm
Ainos stock jumps 5% on healthcare AI expansion plans
April 17, 2026  |  in.investing.comhttps://in.investing.com/news/company-news/ainos-stock-jumps-5-on-healthcare-ai-expansion-plans-93CH-5343294
I was right about SpaceX
Jeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,000%. Now he says SpaceX is shaping up to be the biggest IPO of the decade - and three key milestones just confirmed it. In the past 21 days: SpaceX crossed 10,000 active satellites, Elon filed confidential IPO paperwork with the SEC, and another rocket launched 25 more satellites. Two-thirds of every satellite in orbit now belongs to one company. The public filing could drop any day.tc pixel
May 6 at 1:00 AM  |  Brownstone Research (Ad)
Ainos Gains on Expanding AI News
April 17, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/AIMD/pressreleases/1367660/ainos-gains-on-expanding-ai-news/
Ainos shares rise 5% on push into healthcare AI
April 17, 2026  |  msn.comhttps://www.msn.com/en-us/money/general/ainos-shares-rise-5-on-push-into-healthcare-ai/ar-AA2188hQ
Ainos, Inc.: Ainos, MacKay Memorial Hospital and Topco Scientific Partner to Advance Smell AI Deployment in High-Risk Hospital Environments
April 8, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-04/68147009-ainos-inc-ainos-mackay-memorial-hospital-and-topco-scientific-partner-to-advance-smell-ai-deployment-in-high-risk-hospital-environments-200.htm
See More Ainos Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Ainos? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ainos and other key companies, straight to your email.

About Ainos

Ainos (NASDAQ:AIMD) (NASDAQ: AIMD) is a clinical‐stage biopharmaceutical company dedicated to developing inhalation therapies for patients with chronic pulmonary disorders. The company’s proprietary platform centers on a dry powder inhalation technology designed to deliver therapeutic agents directly to the lungs, potentially improving drug distribution and reducing systemic side effects compared to traditional oral or intravenous formulations.

The lead product candidate, AI‐401, is an inhaled formulation of ibuprofen in a dry powder format. AI‐401 is engineered to target airway inflammation in conditions such as cystic fibrosis and other chronic respiratory diseases. In preclinical studies, the formulation demonstrated favorable pulmonary deposition and sustained release, and it has received orphan drug designation from the U.S. Food and Drug Administration for the treatment of cystic fibrosis.

In addition to AI‐401, Ainos is exploring the application of its dry powder inhalation technology for other anti‐inflammatory and anti‐infective agents, with the goal of expanding its pipeline into multiple respiratory indications. The company collaborates with contract development and manufacturing organizations (CDMOs) to advance product candidates through formulation optimization, toxicology assessments and early clinical trials.

Founded in the United States, Ainos is headquartered in Philadelphia and serves patients and healthcare providers primarily in North America and Europe. The company’s management team comprises executives with extensive experience in respiratory drug development, regulatory affairs and commercial strategy. Ainos aims to leverage its inhalation platform to bring novel pulmonary therapies to market and address unmet medical needs in chronic lung disease.

View Ainos Profile
Earnings Tools